Single and Four-Week Repeated Oral Toxicity Study of CJ-11555 in Sprague-Dawely Rats
![]() |
김일환
(CJ 제약연구소)
이성학 (CJ 제약연구소) 최재묵 (CJ 제약연구소) 박지은 (CJ 제약연구소) 김덕열 (CJ 제약연구소) 노현정 (CJ 제약연구소) 김택로 (CJ 제약연구소) 이상호 (CJ 제약연구소) 김영훈 (CJ 제약연구소) |
1 | 양기화 (2000): 독성병리진단기준해설(랫드편), 국립독성연구소. 의약품등의 독성시험기준. 식품의약품안전청 고시 제 1999-61호, 식품의약품안전청, 서울 |
2 | Gopinath, C., Prentice, D.E. and Lewis, D.J. (1987): Atlas of experimental toxicological pathology, MTP Press, pp. 135 |
3 | Kang, K.W., Choi, S.H., Ha, J.R., Kim. C.W. and Kim, S.G. (2002a): Inhibition of dimethylnitrosamine-induced liver fibrosis by [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] (oltipraz) in rats: suppression of transforming growth factor-beta1 and tumor necrosis factor-alpha expression. Chem. Biol. Interact., 139, 61-67. |
4 | Heusse, D., Marlard, m., Bredenbac, J., Decdouvelaere, B., Leroy, J.P., Bieder, A. and Jumeau, H. (1985). Disposition of 14C-Oltipraz in animals. Pharmacokinetics in mice, rats, and monkeys. Comparison of the biotransformation in the infected mouse and in the schistosomes. Arzneimittelforschung. 35, 1431-1436 |
5 | Crowell, J.A., Page, J.G., Rodman, L.E., Heath, J.E., Goldenthal, E.I., Hall, L.B. and Kellott, G.J. (1997): Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, a potential chemopreventive agent. Fund Appl. Taxical., 35, 9-21 |
6 | Buetler, T.M., Galiaagher, E.P., Wang, C., Stahl, D.L., Hayes, J.D. and Eaton, D.L.(1995): Induction of phase I and II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and Oltipraz. Toxicol. Appl. Pharmacol., 135, 45-57 |
7 | Walter, F.L. and Fred, W,Q. (1989): The clinical chemistry of laboratory animals, Pergamon Press, pp. 179-182, 260 |
8 | Kensler, T.W., Egner, P.A., Dolan, P.M., Groopman, J.D. and Roebuck, B.D. (1987b). Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl1,2-dithiol-3-thione (Oltipraz) and related 1,2-dithio-3thiones and 1,2-dithiol-3-thione. Cancer Res., 47, 4271-4277 |
9 | Ansher, S. (1985): The chemotherapy of schistosomiasis. Ann. Rev. Pharmacol., 25, 485-508 |
10 | Kang, K.W., Kim, Y.G., Cho, M.K., Bae, S.K., Kim, C.W., Lee, M.G. and Kim, S.G. (2002b): Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding proteinmediated stellate cell inactivation. FASEB J., 16, 1988-1990 |
11 | Turton, J. and Hooson, J. (1998): Target organ Pathology, A basic text, Taylor & Francis, pp. 81 |
12 | Kensler, T.W., Egner, .PA., Wang, J.B., Zhu, Y.R., Zhang, B.C., Oian, G.S., Kuang, S.Y., Gange, S.J., Jacobson, L.P., Munoz, A. and Groopman, J.D. (2002a): Strategies for chemoprevention of liver cancer. Eur. J. Cancer Prev., 2, 58-64 |
13 | Greaves, P. (2000): Histopathology of preclinical toxicity studies: Interpretation and relevance in drug evaluation, Second Edition, Elsevier, pp. 114, 227, 576, 638, 760, 850 |
![]() |